Allergic to minoxidil, are there any alternatives? 9/24/2025
The user is allergic to minoxidil and seeks alternatives for hair regrowth. They have been using finasteride for two years, which stopped hair loss but did not promote regrowth.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Nuking DHT at the age of 17 - My Hairloss Stack💪🏼
A 17-year-old shares their hair loss treatment, using oral finasteride, dutasteride, stemoxydine, alfatradiol, and a placebo product, but cannot use minoxidil due to an allergic reaction. Others discuss similar treatments and question the use of dutasteride at a young age.
community Finasteride after 1 year. Is it working?
Finasteride has helped stabilize hair loss, with some users noticing visible improvement and regrowth, particularly in temple areas. Side effects of finasteride are discussed, and minoxidil is suggested as an additional treatment if hair loss resumes.
community Excessive hair growth from Minoxidil
Minoxidil foam and oral finasteride resulted in significant hair regrowth, especially on the hairline, with no side effects from finasteride. The user applied Rogaine 5% for minoxidil.
community What are your unpopular opinions on hair loss and its treatments?
Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.
community [30M] My Aggressive Hair Loss Protocol – 5 Years In, Still Full Coverage
A 30-year-old man shares his successful hair loss protocol, which includes finasteride, Nizoral shampoo, low-level laser therapy, microneedling, and past use of oral minoxidil. He plans to consider dutasteride and possibly hair transplants in the future, while advising caution with crown transplants before age 35.
Related Research
6 / 6 results
research Minoxidil Use in Dermatology, Side Effects and Recent Patents
This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.
research Solid Lipid Nanoparticle–Loaded Acanthus ebracteatus Vahl. Extract for Androgenic Alopecia Treatment: A Randomized, Controlled, Open‐Label, Four‐Arm Parallel‐Group Clinical Study
This study found that a hair serum containing Acanthus ebracteatus extract improved hair regrowth in men with androgenic alopecia, increasing hair count and density of anagen hairs over a 6-month period, with combination treatments showing early effectiveness.
research Exploring the Efficacy and Potential Mechanisms of Topical Periplaneta americana (L.) Extract in Treating Androgenetic Alopecia in a Mouse Model: A Systems Pharmacology and Skin Microbiome Analysis
In this preclinical study, PA-011 derived from Periplaneta americana showed significant hair regrowth effects in androgenetic alopecia mouse models by inhibiting inflammation and oxidative stress, activating hair follicle stem cell proliferation, and normalizing skin microbiota, suggesting promise as an AGA treatment.
research The Effect of Platelet Rich Plasma on Hair Regrowth: A Clinical Study
This study found that Platelet Rich Plasma treatment may safely and effectively promote hair regrowth in patients with pattern hair loss, especially when combined with other topical drugs like finasteride and minoxidil.
research Nonsurgical Therapy for Hair Loss
This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.
research Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population
In this study, combining 2% minoxidil with weekly microneedling significantly improved hair regrowth in women with female pattern hair loss compared to using minoxidil alone, with an 85% effective rate reported in the group receiving both treatments over a 24-week period.